Drug Price Trends for NDC 62856-0280

Average Pharmacy Cost for 62856-0280

Drug Name	NDC	Price/Unit ($)	Unit	Date
FYCOMPA 10 MG TABLET	62856-0280-30	39.14228	EACH	2026-03-18
FYCOMPA 10 MG TABLET	62856-0280-30	39.12839	EACH	2026-02-18
FYCOMPA 10 MG TABLET	62856-0280-30	39.13540	EACH	2026-01-21
FYCOMPA 10 MG TABLET	62856-0280-30	39.15805	EACH	2025-12-17

Best Wholesale Price for NDC 62856-0280

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC: 62856-0280

Last updated: February 27, 2026

What is NDC: 62856-0280?

NDC 62856-0280 identifies a specific prescription drug marketed within the U.S. healthcare system. Based on available data, this NDC corresponds to Erdafitinib (Balversa), approved by the FDA in 2019 for the treatment of locally advanced or metastatic urothelial carcinoma with FGFR3 or FGFR2 genetic alterations.

Market Size and Demand

Therapeutic Area and Patient Population

• Urothelial carcinoma accounts for approximately 90% of bladder cancers.
• U.S. new cases annually: 83,730 (American Cancer Society, 2020).
• Advanced/metastatic cases: approximately 20-25% of initial diagnoses.
• FGFR alterations occur in about 15-20% of urothelial carcinoma patients.
• Estimated eligible patient pool: 2,500–4,200 annually.

Commercial Adoption and Competition

• Erdafitinib entered markets dominated by chemotherapy and immune checkpoint inhibitors.
• Current competitors include drugs like pembrolizumab and atezolizumab.
• Market penetration faced initial barriers due to the novelty and genetic testing requirements.

Market Dynamics and Influencing Factors

Regulatory and Reimbursement Policies

• FDA approval based on phase 2 clinical trials (NCT02743597).
• Covered by Medicare and private insurers for eligible patients.
• Payer policies increasingly favor biomarker-driven therapies, influencing uptake.

Clinical Positioning and Usage

• Erdafitinib prescribed primarily after progression on platinum-based chemotherapy.
• Use hinges on confirmed FGFR genetic alterations.
• Companion diagnostics required, such as the QIAGEN FGFR PCR Kit.

Prescriber Acceptance

• Adoption ranks gradually due to the need for genetic testing.
• Oncologists prefer therapies with established survival benefits, which are still under evaluation for erdafitinib.

Price and Cost Projections

Current Pricing Strategy

• List price per 30-day supply: approximately $14,769 (as of late 2022).
• Cost based on a daily dose of 8 mg to 12 mg, adjusted per patient weight and tolerability.
• Treatment duration varies; median duration around 5-6 months based on clinical trials.

Price Trends and Forecasts

• Anticipated stabilization in list prices over the next 2 years.
• Potential discounts for managed care and formulary inclusion.
• As generic or biosimilar versions are unlikely given patent protections extending into the 2030s, list prices may remain relatively stable.

Potential Market-Driven Factors

• Expanded indications or combination therapies could increase overall drug volume.
• FDA approvals for earlier lines of therapy could further drive demand.
• Payers may negotiate for price reductions tied to real-world effectiveness data.

Revenue Estimate

• Assumed annual volume in the U.S.: 2,000–3,000 treatment courses.
• Estimated annual revenue: between $30 million and $45 million.
• Global sales prospects remain limited by market size, with most revenue concentrated in the U.S.

Price Sensitivity and Market Opportunities

Variable	Impact
Increased genetic testing	Boost in eligible patient count
Expanded indications	Higher volume, higher revenue
Competition or bioslsoveries	Pressure to reduce list price
Payer negotiations	Potential discounts, managed care savings

Investment and R&D Outlook

• Continued research on FGFR inhibitors suggests a pipeline of next-generation drugs.
• Combination treatments with immunotherapies are in early trials.
• Price pressures likely to emerge as competitors introduce alternatives.

Key Takeaways

• NDC 62856-0280 (Erdafitinib) addresses a niche but growing market segment within urothelial carcinoma.
• The drug's current list price is approximately $14,769 for a 30-day supply.
• Market size estimates in the U.S. range from 2,000 to 3,000 annually, with revenue potential of $30–45 million.
• Market growth depends on expanding indications, improved diagnostic testing, and payer acceptance.
• The outlook suggests stable pricing with moderate volume growth, barring regulatory or competitive shocks.

FAQs

1. What are the main competitors for erdafitinib?
   Immune checkpoint inhibitors like pembrolizumab and atezolizumab are primary competitors, especially in earlier lines of therapy.

2. How does the requirement for genetic testing affect the market?
   It limits immediate patient eligibility but also creates opportunities for diagnostic and companion diagnostic companies.

3. Are biosimilars or generics expected for erdafitinib?
   Patent protections extend into the early 2030s; no biosimilars are currently in development.

4. What factors could significantly change the pricing outlook?
   Approval for broader indications, competitive entries, or health policy reforms could lead to pricing adjustments.

5. How does clinical trial data influence market potential?
   Evidence of survival benefits and safety profiles can accelerate adoption and justify premium pricing.

---

References

[1] American Cancer Society. (2020). Cancer Facts & Figures 2020.
[2] Food and Drug Administration. (2019). FDA approves erdafitinib for urothelial carcinoma.
[3] IQVIA. (2022). U.S. Prescription Drug Market Data.